Posted by Michael Wonder on 13 Dec 2024
FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma
13 December 2024 - Today, the FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Efficacy was evaluated in Study CK-301-101, a multi-centre, multi-cohort, open-label trial in 109 patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who were not candidates for curative surgery or curative radiation.
